Neogenomics (NEO) Consolidated Net Income (2010 - 2026)

Neogenomics has reported Consolidated Net Income for 17 years, with the latest figure at -$17.1 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 34.01% year-over-year to -$17.1 million; the trailing twelve-month figure through Mar 2026 stood at -$99.2 million (down 27.87% YoY), and the FY2025 full-year result was -$108.0 million, down 37.22% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$17.1 million, down from -$9.9 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$9.9 million in Q4 2025, with the low at -$49.4 million in Q1 2022.
• Historically, Consolidated Net Income has averaged -$25.7 million across 5 years, with a median of -$24.3 million in 2023.
• Annual changes were most pronounced in 2022 — Consolidated Net Income tumbled 146.53% — and 2023, when it soared 49.76%.
• Neogenomics' Consolidated Net Income stood at -$22.7 million in 2022, then jumped by 36.85% to -$14.3 million in 2023, then decreased by 6.97% to -$15.3 million in 2024, then soared by 35.52% to -$9.9 million in 2025, then sank by 73.12% to -$17.1 million in 2026.
• The last three Consolidated Net Income figures came in at -$17.1 million (Q1 2026), -$9.9 million (Q4 2025), and -$27.1 million (Q3 2025), per Business Quant data.